Bildkälla: Stockfoto

Ascelia Pharma Q1: Progress towards submission and partner discussions - Redeye

Ascelia’s actual Q1 result is a very minor event compared with the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base is contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).

Ascelia’s actual Q1 result is a very minor event compared with the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base is contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).
Börsvärldens nyhetsbrev
ANNONSER